Drug Trial Radar · NCT06755541
Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis: a Real World Study
Last checked: Nov 20, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Jan 30, 2024
Primary completion
Dec 2035
Study completion Dec 2035
Sponsor
- Lead sponsor
- Xijing Hospital of Digestive DiseasesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Fenofibrate in Combination with Ursodeoxycholic Acid in Subjects with Primary Biliary Cholangitis (PBC)
Conditions
- Primary Biliary Cholangitis (PBC)
Interventions
Fenofibrate in Combination With Ursodeoxycholic AcidDrug
Experimental: Fenofibrate 200 mg Capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment emergent adverse events (TEAEs)Time frame: Through study completion, up to 120 Months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Xijing hospital
Xi'an, Shaanxi, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.